LAUSANNE, Switzerland, April 16, 2015 /PRNewswire/ -- Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced that preclinical data on the investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR 12,3 inhibitor) will be presented at the 2015 Annual meeting of the American Association for Cancer Research (AACR) taking place in Philadelphia.
“Oncology has and will continue to benefit from combined and targeted therapies. Results from these preclinical studies underscore the potential clinical value of our two anti-cancer targeted therapies,” said Dr Nigel McCracken, Vice President, Translational Medicine. “Currently both Debio 1143 and Debio 1347 are in Clinical Development and Debiopharm remains committed to exploring new combinations and new indications to provide improved benefit to patients suffering from cancers.”
AACR 2015 Abstract
| Compound | Title | Date and Time | N° |
| Debio 1143 | SMAC mimetic and radiotherapy synergize to enhance
| Sun, Apr 19, | #283 |
| Debio 1143 synergizes with taxanes, topoisomerase
| Mon, Apr 20, | #2529 | |
| The IAP inhibitor Debio 1143 reverses carboplatin resistance
| Mon, Apr 20, | #2700 | |
| Debio 1347 | Characterization of two novel oncogenic FGFR2 fusions cholangiocarcinoma
| Sun, Apr 19, | #689 |
| Formulation switch and pharmacokinetics/pharmacodynamics of
| Mon, April 20, | Abstract | |
| Additional poster regarding Debio 1347 to be presented by Chugai | Sun, Apr 19, | Abstract |
About Debiopharm International SA
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.
For more information, please visit: www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
| Debiopharm International SA Contact | Additional Media Contacts |
| Christelle Tur | In London |
| Communication Coordinator | Maitland |
| Martin Barrows | |
| Tel: +41 (0)21 321 01 11 | |
| Tel: +44 (0)20 7395 0444 | |
| In New York | |
| Russo Partners, LLC | |
| Marissa Goberdhan | |
| Account Executive | |
| Tel: +1 212-845-4253 |
SOURCE Debiopharm Group
Help employers find you! Check out all the jobs and post your resume.
